復星醫藥(600196.SH):復宏漢霖與Accord簽訂補充協議 新增60mg、420mg規格注射劑
格隆匯 6 月 24日丨復星醫藥(600196.SH)公佈,2020年6月24日,復宏漢霖與Accord簽訂《AmendmenttoLicenseAgreement》(以下簡稱“《補充協議》”),雙方就新增該產品許可規格及相應里程碑付款安排及銷售提成比例調整等達成一致。
《補充協議》主要內容:
1、在原許可150mg規格注射劑的基礎上,新增許可該產品60mg、420mg規格注射劑(以下簡稱“本次新增許可規格”)。
2、付款Accord向復宏漢霖支付首付款及里程碑費用總額由原約定的4,050萬美元增加至4,358萬美元,其中:因新增許可規格而增加里程碑費用至多308萬美元。
(1)里程碑付款
本次新增許可規格相關的里程碑費用至多308萬美元,且相關費用均應於相關事件發生後的45日內支付,具體安排如下:
①里程碑付款不超過154萬美元:應於歐洲藥品管理局(EMA)受理該產品新增規格上市許可申請後支付;
②里程碑付款不超過37.5萬美元:應於歐洲藥品管理局(EMA)授予該產品新增規格上市許可後支付;
③里程碑付款不超過116.5萬美元:應於Accord收到工藝驗證批次中可用於商業化的產品後支付。
(2)銷售提成
Accord應在協議約定期間根據該產品在區域內的淨銷售額達成情況支付利潤提成,利潤提成的比例區間將從原約定的淨銷售額產生利潤的13.5%至25%,調整為15%至26.5%
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.